Related Experiment Video
Updated: Apr 8, 2026
12:33
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
66.3K
Incretin manipulation in diabetes management
Joseph M Pappachan1, A V Raveendran1, Rajagopalan Sriraman1
1Joseph M Pappachan, Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, WV10 0QP Wolverhampton, United Kingdom.
World Journal of Diabetes
|July 2, 2015
Summary
Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and DPP-4 inhibitors, offer significant benefits for type 2 diabetes management. These treatments effectively lower hemoglobin A1c, aid weight management, and have a low risk of hypoglycemia.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Incretin-based therapies have transformed type 2 diabetes mellitus (T2DM) treatment.
- Glucagon-like peptide-1 (GLP-1) plays a key role in glucose homeostasis and offers extrapancreatic benefits.
Purpose of the Study:
- To discuss the therapeutic manipulation of the incretin system for T2DM management.
- To highlight the benefits and safety of incretin-based therapies.
Main Methods:
- Review of current literature on incretin-based therapies.
- Analysis of clinical trial data and meta-analyses regarding efficacy and safety.
Main Results:
- Incretin-based therapies (GLP-1 analogues, DPP-4 inhibitors) significantly reduce hemoglobin A1c.
- These therapies demonstrate favorable effects on body weight and a low risk of hypoglycemia.
- Safety and tolerability are comparable to other antidiabetic medications, with pancreatitis risk concerns largely dismissed.
Conclusions:
- Incretin-based therapies are a cornerstone in modern T2DM management.
- The incretin system offers a valuable therapeutic target for improving glycemic control and patient outcomes.
- Further research continues to explore the full potential of incretin-based treatments.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
963
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
963
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
3.1K